Skip to main content
. Author manuscript; available in PMC: 2021 Apr 20.
Published in final edited form as: J Thorac Oncol. 2017 Oct 31;13(2):237–245. doi: 10.1016/j.jtho.2017.10.010

Table 3.

Immunohistochemistry for Different Histologic Components in Combined SCLC (n = 10)

Case Component CD56 ChrA Syn TTF-1 CK7 Ki67 p63 Napsin A
1 SCLC + focal/weak+ strong+ + + ~100 np
GUH54 Squamous 80 + np
2 SCLC + Patchy+ + ~100 np
GUH81 Squamous 80 + np
3 SCLC + Focal+ + + Patchy+ np n/a
GUH95 Poorly differentiated adenocarcinoma + np n/a Focal+
4 SCLC + np Patchy+ 80 np
GUH98 Squamous np + 50-60 + np
5 SCLC Patchy+ + np np np
GUH90 Squamous np np np
6 SCLC + + 70-80 np
GUH93 Squamous 40-50 + np
7 SCLC + + + + + n/a
GUH68 Adenocarcinoma 30 n/a +
8 SCLC + + + + + 80 n/a np
GUH45 Poorly differentiated LCNEC + Patchy+ + 20 n/a np
9 SCLC + + + + 50 n/a np
GUH164 LCNEC + + + + Dot-like+ 80 n/a np
10 SCLC with clear cell change + Focal+ 80 n/a np
GUH167 LCNEC + Focal+ 100 n/a np

ChrA, chromogranin A; Syn, synaptophysin; TTF-1, thyroid transcription factor 1; CK7, cytokeratin 7; GUH, Georgetown University Hospital; n/a, not applicable; np, not present; LCNEC, large cell neuroendocrine carcinoma.